The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.
Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role f...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS Pathogens |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI |
id |
doaj-835ee4875e3c44228c2249d9b9ebd927 |
---|---|
record_format |
Article |
spelling |
doaj-835ee4875e3c44228c2249d9b9ebd9272021-04-21T17:27:18ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742012-01-0188e100284710.1371/journal.ppat.1002847The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo.Allison GrosethAndrea MarziThomas HoenenAstrid HerwigDon GardnerStephan BeckerHideki EbiharaHeinz FeldmannAmong the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a unique possibility to directly investigate the role of an entire filovirus protein in pathogenesis. To this end we have generated recombinant ZEBOV (rZEBOV) and REBOV (rREBOV), as well as chimeric viruses in which the glycoproteins from these two virus species have been exchanged (rZEBOV-RGP and rREBOV-ZGP). All of these viruses could be rescued and the chimeras replicated with kinetics similar to their parent virus in tissue culture, indicating that the exchange of GP in these chimeric viruses is well tolerated. However, in a mouse model of infection rZEBOV-RGP demonstrated markedly decreased lethality and prolonged time to death when compared to rZEBOV, confirming that GP does indeed contribute to the full expression of virulence by ZEBOV. In contrast, rREBOV-ZGP did not show any signs of virulence, and was in fact slightly attenuated compared to rREBOV, demonstrating that GP alone is not sufficient to confer a lethal phenotype or exacerbate disease in this model. Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence.https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Allison Groseth Andrea Marzi Thomas Hoenen Astrid Herwig Don Gardner Stephan Becker Hideki Ebihara Heinz Feldmann |
spellingShingle |
Allison Groseth Andrea Marzi Thomas Hoenen Astrid Herwig Don Gardner Stephan Becker Hideki Ebihara Heinz Feldmann The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathogens |
author_facet |
Allison Groseth Andrea Marzi Thomas Hoenen Astrid Herwig Don Gardner Stephan Becker Hideki Ebihara Heinz Feldmann |
author_sort |
Allison Groseth |
title |
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
title_short |
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
title_full |
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
title_fullStr |
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
title_full_unstemmed |
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
title_sort |
ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS Pathogens |
issn |
1553-7366 1553-7374 |
publishDate |
2012-01-01 |
description |
Among the Ebola viruses most species cause severe hemorrhagic fever in humans; however, Reston ebolavirus (REBOV) has not been associated with human disease despite numerous documented infections. While the molecular basis for this difference remains unclear, in vitro evidence has suggested a role for the glycoprotein (GP) as a major filovirus pathogenicity factor, but direct evidence for such a role in the context of virus infection has been notably lacking. In order to assess the role of GP in EBOV virulence, we have developed a novel reverse genetics system for REBOV, which we report here. Together with a previously published full-length clone for Zaire ebolavirus (ZEBOV), this provides a unique possibility to directly investigate the role of an entire filovirus protein in pathogenesis. To this end we have generated recombinant ZEBOV (rZEBOV) and REBOV (rREBOV), as well as chimeric viruses in which the glycoproteins from these two virus species have been exchanged (rZEBOV-RGP and rREBOV-ZGP). All of these viruses could be rescued and the chimeras replicated with kinetics similar to their parent virus in tissue culture, indicating that the exchange of GP in these chimeric viruses is well tolerated. However, in a mouse model of infection rZEBOV-RGP demonstrated markedly decreased lethality and prolonged time to death when compared to rZEBOV, confirming that GP does indeed contribute to the full expression of virulence by ZEBOV. In contrast, rREBOV-ZGP did not show any signs of virulence, and was in fact slightly attenuated compared to rREBOV, demonstrating that GP alone is not sufficient to confer a lethal phenotype or exacerbate disease in this model. Thus, while these findings provide direct evidence that GP contributes to filovirus virulence in vivo, they also clearly indicate that other factors are needed for the acquisition of full virulence. |
url |
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22876185/pdf/?tool=EBI |
work_keys_str_mv |
AT allisongroseth theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT andreamarzi theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT thomashoenen theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT astridherwig theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT dongardner theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT stephanbecker theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT hidekiebihara theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT heinzfeldmann theebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT allisongroseth ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT andreamarzi ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT thomashoenen ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT astridherwig ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT dongardner ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT stephanbecker ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT hidekiebihara ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo AT heinzfeldmann ebolavirusglycoproteincontributestobutisnotsufficientforvirulenceinvivo |
_version_ |
1714666167178625024 |